"Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC BIOCAD) With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid Arthritis"

PHASE3CompletedINTERVENTIONAL

Enrollment

159

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

August 31, 2017

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL

Acellbia

Acellbia is rituximab biosimilar, monoclonal antibody which binds CD20.

DRUG

Placebo

Placebo solution will look identical to the Acellbia solution.

DRUG

Methotrexate